About Indegene Limited

Established in 1998, Indegene Limited is a digital-first life sciences commercialization company that serves biopharmaceutical, emerging biotech and medical devices companies worldwide. It supports clients across the product life cycle—from drug development and clinical trials to regulatory submissions, pharmacovigilance and complaints management, and sales and marketing—using domain expertise and fit-for-purpose technology; its portfolio spans commercial, medical, regulatory and R&D operations of life sciences companies. The company is registered in Karnataka with its registered office in Bengaluru, India. 

Indegene Limited Milestone 

Indegene marked its 25th anniversary during the year; its early milestones included introducing medical education services to Indian pharmaceutical companies in 2000 and launching the Indegene Mobile Health System the same year . The company became publicly listed on the National Stock Exchange of India Limited (NSE) and BSE Limited on May 13, 2024. 

Indegene operates through subsidiaries and step-down subsidiaries across the USA, Canada, England/UK, Germany, Switzerland, Ireland, Singapore, China, Mexico and Japan, reflecting a broad presence across North America, Europe and Asia. As of the latest year, the company has 18 subsidiaries (including subsidiaries of subsidiaries). Indegene reported a workforce of 4,367 employees as of March 31, 2024 .

Indegene Limited Key Management

• Manish Gupta — Chief Executive Officer and Executive Director
• Dr. Sanjay S Parikh — Executive Director
• Suhas Prabhu — Chief Financial Officer
• Srishti Ramesh Kaushik — Company Secretary

Latest Updates on Indegene Limited

• Public listing: Indegene’s equity shares were listed on NSE (symbol: INDGN) and BSE on May 13, 2024, following its initial public offering.
• Strategic acquisition: The company acquired a controlling stake in Trilogy Writing & Consulting GmbH, a Germany-, UK- and US-based medical writing consultancy with a 22+ year track record and expertise spanning oncology, immunology, neurosciences, urology, anti-infectives, endocrinology and respiratory diseases. Trilogy supports regulatory submissions across leading health authorities including the US FDA, EU EMA, Health Canada, UK MHRA, China NMPA and Japan PMDA.
• Group reorganisation and expansion: During the year, Indegene restructured certain holdings under Indegene Ireland Limited, which acquired Indegene Fareast Pte. Ltd. (Singapore) on December 28, 2023, Indegene Europe LLC (Switzerland) on December 27, 2023, and Indegene Lifesystems Consulting (Shanghai) Co. Ltd. (China) on February 29, 2024. The company also incorporated Indegene Healthcare UK Limited on December 7, 2023.
• Workforce: Indegene reported 4,367 employees as of March 31, 2024.
• Nature of business: The company confirmed there was no change in the nature of its business during the period under review.